Chris Chen, CEO of WuXi Biologics, discusses his organization’s approach to ensuring consistent quality, reliability, and speed of biologics development and manufacturing.
Overall, the company’s specialty CDMO business grew in the low-double digits during the first quarter of fiscal 2026, with expectations of mid-teens growth this year.
The company is selling contract development and manufacturing organization sites in Tennessee, Maryland, and the UK, as well as a cell solutions site in California.
Of about $600 billion in domestic investments announced in 2025, only $60 billion worth of estimated capital expenditures have specific amounts and locations, finds CBRE.
Tariff refunds are a leadership call for pharmaceutical manufacturers, and executives are weighing whether recovery efforts justify the operational lift.
Since SK bioscience acquired a 60% stake in the CDMO, the company has undertaken a “full-scale drive” to expand its business in vaccines and biopharmaceuticals.
The CDMO’s “conservative” guidance is due to limited visibility around a pending customer confirmation for a large contract that could impact sales growth this year.
Despite the legal setback for President Trump’s country-specific tariffs, he retains the authority to impose Section 232 tariffs on pharmaceuticals imported to the U.S.
To counter the Chinese government’s investment, the U.S. must make a coordinated effort to grow biomanufacturing base, argues a bipartisan commission created by Congress.
The CDMO has strengthened its oral solid dose and antibody-drug conjugate capabilities as drugmakers diversify away from China and expand onshore production.
Organic revenue for the company’s manufacturing solutions decreased 2.1%, driven by lower revenue in its contract development and manufacturing organization segment.
As artificial intelligence tools proliferate, the real challenge is not generating ideas but turning them into chemically feasible and manufacturable paths.
The pharma giant has added to its inventory of orforglipron in anticipation of a favorable regulatory decision by the U.S. Food and Drug Administration.
Aiming to be Europe’s top life sciences economy by 2030, Britain must create a better business environment, argued panelists at Fujifilm’s grand opening in Teesside.
With 17 facilities in 10 countries, geopolitical uncertainty last year weighed on the Swedish-headquartered contract development and manufacturing organization.
Production is highly concentrated globally making lower- and middle-income regions vulnerable to supply shocks, regulatory bottlenecks, and slow pandemic response.
Industrializing the manufacturing of these complex therapies is critical to ensure scalability and commercial viability, says the Alliance for Regenerative Medicine.
2025 was a strong year for drugs approved by the agency with record-high outsourcing penetration. Lonza, Thermo Fisher, and Catalent remain the leaders.
Investments in its network include the company’s CDMO business in the Toronto area, where it is building a new GMP biologics facility slated for completion in 2026.
The agency will select new pharma manufacturing facilities for the pilot aimed at reducing inspection-related delays and creating a more predictable regulatory pathway.
It is the largest increase of the four major industries tracked by commercial real estate firm Newmark, which analysts contend is the start of a super-cycle for the sector.
In addition to new sites, which will be announced later, the company will expand its existing manufacturing facilities in Beijing, Qingdao, Taizhou, and Wuxi.
It will take the company years to recoup its investment in the large-scale mammalian drug substance facility, acquired in 2024 from Roche for $1.2 billion.
While recent setbacks have hit its cell and gene therapy business, the contract development and manufacturing organization says fundamentals are strong.
The Swiss-headquartered CDMO is acquiring a commercial-scale site in Wilmington, Delaware and a clinical active pharmaceutical ingredient facility in Athens, Georgia.